Edition:
United States

Neogenomics Inc (NEO.OQ)

NEO.OQ on NASDAQ Stock Exchange Capital Market

13.25USD
14 Dec 2018
Change (% chg)

$-0.18 (-1.34%)
Prev Close
$13.43
Open
$13.27
Day's High
$13.44
Day's Low
$13.03
Volume
326,042
Avg. Vol
231,982
52-wk High
$19.02
52-wk Low
$7.08

Latest Key Developments (Source: Significant Developments)

Neogenomics Announces Pricing On Secondary Offering Of 10.8 Mln Shares
Wednesday, 12 Dec 2018 07:34am EST 

Dec 12 (Reuters) - Neogenomics Inc ::NEOGENOMICS ANNOUNCES PRICING ON SECONDARY OFFERING OF COMMON STOCK BY SELLING STOCKHOLDER.NEOGENOMICS INC - PRICING OF SECONDARY OFFERING OF 10.8 MILLION SHARES OF COMMON STOCK OF COMPANY BY GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES.  Full Article

Neogenomics Reports 17 Pct Revenue Growth To Record $69 Mln
Tuesday, 30 Oct 2018 07:00am EDT 

Oct 30 (Reuters) - Neogenomics Inc ::NEOGENOMICS REPORTS 17% REVENUE GROWTH TO RECORD $69 MILLION.Q3 REVENUE $69.1 MILLION VERSUS I/B/E/S VIEW $66.3 MILLION.QTRLY EARNINGS PER SHARE $0.02.SEES FY 2018 CONSOLIDATED REVENUE IN THE RANGE OF $270 MILLION - $272 MILLION.SEES FY 2018 GAAP DILUTED EPS IN THE RANGE OF $0.04 - $0.05.SEES FY 2018 ADJUSTED DILUTED EPS IN THE RANGE OF $0.17 - $0.19.Q3 EARNINGS PER SHARE VIEW $0.02 -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $0.15, REVENUE VIEW $268.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Neogenomics Signs Definitive Agreement To Acquire Genoptix
Tuesday, 23 Oct 2018 07:01am EDT 

Oct 23 (Reuters) - Neogenomics Inc ::NEOGENOMICS SIGNS DEFINITIVE AGREEMENT TO ACQUIRE GENOPTIX.NEOGENOMICS INC - DEAL FOR $125 MILLION IN CASH AND 1 MILLION SHARES OF NEOGENOMICS COMMON STOCK.NEOGENOMICS INC - ACQUISITION IS EXPECTED TO CONTRIBUTE $85 MILLION OF REVENUE AND BREAK-EVEN EBITDA IN YEAR ONE.NEOGENOMICS INC - ACQUISITION IS EXPECTED TO CONTRIBUTE $25 MILLION OF COST SYNERGIES OVER TIME, AND 25% EBITDA MARGIN BY END OF YEAR THREE.  Full Article

NeoGenomics reports Q3 adj earnings per share of $0.01
Wednesday, 25 Oct 2017 07:00am EDT 

Oct 25 (Reuters) - Neogenomics Inc :NeoGenomics reports revenue of $63.1 million on 17 percent volume growth and 11 percent reduction in average cost per test in the third quarter of 2017.Q3 adjusted earnings per share $0.01.Q3 revenue $63.1 million versus I/B/E/S view $63.5 million.Q3 earnings per share view $0.02 -- Thomson Reuters I/B/E/S.Sees Q4 loss per share $0.03 to $0.04.Sees Q4 revenue $65 million to $67 million.Q3 GAAP loss per share $0.10.Q4 earnings per share view $0.04, revenue view $66.8 million -- Thomson Reuters I/B/E/S.NeoGenomics Inc - expects ‍Q4 adjusted diluted EPS to be $0.04 - $0.05 per share​.  Full Article

NeoGenomics sees Q3 revenue of about $63.1 mln
Thursday, 12 Oct 2017 04:01pm EDT 

Oct 12 (Reuters) - NeoGenomics Inc :NeoGenomics announces preliminary quarter 3 results, financial impacts of hurricanes and summary quarter 4 guidance.NeoGenomics Inc - ‍it expects to report quarter 3 revenue of approximately $63.1 million and adjusted EBITDA of approximately $6.0 million​.NeoGenomics Inc - ‍NeoGenomics estimates that hurricanes Harvey and Irma depressed revenue by approximately $1.0 million in quarter 3​.NeoGenomics inc - ‍in addition, as a result of divestiture of pathlogic, Q3 revenue will be approximately $1.3 million less than in quarter 2​.NeoGenomics Inc - ‍expects consolidated revenue of $65 million - $67 million and adjusted EBITDA of $9 million -10 million in Q4​.NeoGenomics-For Q3,expects to record $1.3 million revenue adjustment to reflect change in process for estimating revenue for unbilled tests at quarter-end​.Q3 revenue view $65.9 million -- Thomson Reuters I/B/E/S.Q4 revenue view $69.1 million -- Thomson Reuters I/B/E/S.  Full Article